Cell-cycle targeted cancer therapy: clinical advances, biological gaps, and the emergence of selective CDK4 inhibitors
Abstract Cyclin-dependent kinase (CDK) 4/6 inhibitors have reshaped the therapeutic landscape for hormone receptor (HR)-positive breast cancer and firmly established…
